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independently was suggested by Mason,1 and our recent data3
show that it actually occurs. We suggest that blood oxygen
level-dependent magnetic resonance imaging requires further
validation for use in estimating renal oxygenation. One
possible approach would be to use newer functional magnetic
resonance imaging techniques that employ extracellular pO2
reporter molecules.4
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It is indeed gratifying that our caveats and concerns have
been validated. We believe that the BOLD investigations
can be very useful, since they are noninvasive, using blood
as the reporter molecule. However, as the correspondents1
recognize there is interplay of oxygen delivery, consump-
tion, and clearance, and thus, assumptions are needed
when inferring changes in tissue pO2. Moreover, arterio-
venous (AV) shunting may separate tissue and capillary
phenomena from bulk AV measurements.
The correspondents cite their recent observations in rat
and rabbit kidney cortex and medulla on the basis of
polarographic electrodes, fluorescent fiber optic probes,
and arterial and venous blood samples.2 An MRI approach
could be even more powerful by interrogating multiple
locations simultaneously and providing quantitative pO2
based on reporter molecules, such as hexafluorobenzene3
or hexamethyldisiloxane.4 However, routine use in deep
organs, such as kidney, has been hindered by difficulty in
placing the exogenous reporter molecule, albeit using a
very fine needle. We certainly encourage such investiga-
tions. In the meantime, it would be interesting to apply
BOLD MRI to the models of Evans et al. The BOLD
measurements would be expected to be sensitive to
capillary oxygenation, which may or may not be associated
with bulk venous blood following major shunting. It could
also be valuable to apply both T1 and T2* measurements,
since these are attributable, respectively, to tissue5 and
vascular oxygenation.6
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To the Editor: We found the post hoc survival analysis of
Sevelamer in the incident hemodialysis patients thought
provoking.1 It is known from Dr Block’s original study that,
as compared to Calcium-containing binders, Sevelamer
slowed the progression of coronary artery calcification
(CAC) scores at 18 months.2 The current analysis shows
that mortality was predicted by phosphate binder use in the
first 18 months (lower mortality with Sevalamer) and by
‘baseline’ CAC score, but not by CAC score at 18 months.
This begs the question as to whether the slowing of
progression of CAC score using Sevelamer has any direct
effect on survival or is it possible that the survival benefit of
Sevelamer is independent of effects on calcification? Since the
patients underwent EBCT at regular intervals up to 18
months, the authors are in unique position to examine if
change (delta) in CAC score at 18 months had any direct
effect on survival.
1328 Kidney International (2007) 71, 1322–1329
l e t t e r t o t h e e d i t o r
1. Block GA, Raggi P, Bellasi A et al. Mortality effect of coronary calcification
and phosphate binder choice in incident hemodialysis patients. Kidney Int
2007; 71: 438–441.
2. Block GA, Spiegel DM, Ehrlich J et al. Effects of Sevelamer and calcium on
coronary artery calcification in patients new to hemodialysis. Kidney Int
2005; 68: 1815–1824.
SV Badve1 and PO Magner1
1Division of Nephrology, University of Ottawa and The Ottawa Hospital,
Ottawa, Canada
Correspondence: SV Badve, Division of Nephrology, University of Ottawa
and The Ottawa Hospital, 1967 Riverside Drive, Ottawa, ON, K1H 7W9,
Canada. E-mail: sbadve@ottawahospital.on.ca
Kidney International (2007) 71, 1322–1329 1329
l e t t e r t o t h e e d i t o r
